Our study revealed the relationship between two markers (TNFR2 and CCR8) of tumour-infiltrating Tregs and suggested TNFR2+CCR8+ Tregs as a potential immunotherapeutic target to enhance antitumour immunity and strengthen anti-PD1 treatment efficacy in CRC patients. This evidence concerns the gene TNFRSF1B and neoplasm.